Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

PURPOSE: Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Garon, Edward B., Hellmann, Matthew D., Rizvi, Naiyer A., Carcereny, Enric, Leighl, Natasha B., Ahn, Myung-Ju, Eder, Joseph Paul, Balmanoukian, Ani S., Aggarwal, Charu, Horn, Leora, Patnaik, Amita, Gubens, Matthew, Ramalingam, Suresh S., Felip, Enriqueta, Goldman, Jonathan W., Scalzo, Cathie, Jensen, Erin, Kush, Debra A., Hui, Rina
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2019
Subjects:
RAPID COMMUNICATION
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768611/
https://ncbi.nlm.nih.gov/pubmed/31154919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00934
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items